Mice treated with 20 mg·kg−1 of LAT9997 had more moderate lymphopenia and possessed significantly greater numbers of circulating B cells, CD4+ T cells, CD8+ T cells, and double-negative T cells (Supplementary Figure 4D, F–J). Here, CD8A is linked to lymphopenia.